ARTICLES BY ALEXANDER K. AUST
-
![nanoparticles-drug molecule-GettyImages-1428647836]( "Tracking 4 Payload Trends In Drug Delivery Development")
Tracking 4 Payload Trends In Drug Delivery Development1/22/2024Amid new research and development in nanocarriers, market attention has shifted toward payloads and enhancing compatibility. This discussion explores the latest trends and includes a research database.
-
![T Cell GettyImages-538032878]( "6 PEG Alternatives You Should Be Thinking About")
6 PEG Alternatives You Should Be Thinking About11/22/2023PEGylation is a common way to minimize off-target effects and general toxicity, but it also poses life-threatening risks because it prolongs the drug's time in the bloodstream. Scientists are exploring these alternatives to combat the risk.
-
![reasearch student scientist GettyImages-542576668]( "4 Major Trends In Lipid Nanoparticle Research")
4 Major Trends In Lipid Nanoparticle Research9/7/2023When biopharmaceutical consultant Alexander Aust noticed a flood of new research on lipid and polymer nanoparticles pouring out of universities, he started collecting it. Soon, his collection grew enough to reveal trends in the research of nanoparticles in oncology, neurology, infectious disease, and, of course, nucleic acids. He provides a quick overview of those trends and the database with links to published research — more than 300 articles published since 2020.
-
![Molecule]( "An Independent Expert's Guide To Picking Nanoparticle Manufacturing Equipment")
An Independent Expert's Guide To Picking Nanoparticle Manufacturing Equipment7/26/2023Until recently, nanoparticle manufacturers had to change equipment between preclinical, clinical, and commercial phases. Advances in technology offer more flexibility allowing manufacturers to turn up the dial on the same machines — from early development all the way to commercialization.
Alexander K. Aust
Alexander K. Aust, M.S., MBA, is the co-founder and owner of Aust Business Solutions, a pharmaceutical consultancy based in Maryville, Tennessee. The firm specializes in the manufacture of cell and gene therapies and sterile, parenteral drug products with services including facility design and construction, corporate strategy, marketing, business development, market research, project management, technology transfers, CDMO selection, quality audits, supply chain management, and process development of drug delivery systems. The firm has helped companies increase capabilities and capacities related to mRNA-LNP formulation, testing, and cGMP manufacturing. The firm has also established and qualified cGMP drug product and biologics facilities that can manufacture preclinical, clinical, and commercial drugs to meet global regulatory requirements. Aust earned his MBA from Ball State University and an M.S. degree from Purdue University in molecular and cellular biology.